Based on 3 reference(s) in Google Scholar 8 10 3

Axon 3739

CAS [610318-54-2]

MF C34H33ClF3NO3
MW 596.08

  • Purity: 99%
  • Optical purity: 99% e.e.
  • Soluble in DMSO



RGX-104 is an oral, selective LXR (Liver-X Nuclear Hormone Receptor) agonist, and a first-in-class immunotherapy agent. It activates the expression of the ApoE gene and reverses the immunosuppressive effects of cancer by targeting the LXR/ApoE pathway that regulates the innate immune response to cancer. This next-generation therapy has two key effects on the innate immune system that drive tumor immunity: it depletes myeloid-derived suppressor cells (MDSCs) and stimulates dendritic cells (DCs). MDSCs block the ability of T cells to become active, while stimulated DCs are required for proper activation (priming) of T cells.

KEYWORDS: RGX-104 | Supplier | LXR agonist | RGX104 | RGX 104 | SB-742881 | SB742881 | CT-RGX104 | CAS [610318-54-2] | Metabolism | LXR | Agonist | Receptors

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...